Thrombolytic therapy in acute myocardial infarction: Comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin

Circulation

Volumn 98, Issue 23, 1998, Pages 2527-2533

  Hoffmeister, Hans Martin ^a   Szabo, Sebastian ^a   Kastner, Christof ^a   Beyer, Martin E ^a   Helber, Uwe ^a   Kazmaier, Silke ^a   Wendel, Hans Peter ^a   Heller, Wolfgang ^a   Seipel, Ludger ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alteplase; Coagulation; Infarction; Streptokinase; Thrombolysis

Indexed keywords

ALTEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; ENZYME ACTIVATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032497902     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.23.2527     Document Type: Article

References (37)

1. The GUSTO Investigators. An international randomized trial and comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
2. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P. Comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328:673-679.
3. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC,. Sobel B, Cupples LA, Braunwald E. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. Am J Cardiol. 1996;78:503-510.
4. Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet. 1990;1:481-482.
5. Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis. 1991;5:217-224.
6. Goto S, Kawai Y, Abe S, Takahashi E, Handa S, Ogawa S, Watanabe K, Hori S, Ikeda. Y. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction. Angiology. 1994;45:273-281.
7. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.
8. Rapold HJ, de Bono D, Arnold AER, Arnout J, de Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Circulation 1992;85: 928-934.
9. Baglin TP, Luddington R, Jennings I, Richards EM. Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator. Lancet. 1993;341:505. Abstract.
10. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995;25:203-209.
11. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER, Thrombolytic therapy wíth tíssue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988;72:616-620.
12. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of the coagulation, the fibrinolytic, and the kallikrein-kinin system in the acute and postacute phase in patients with unstable angina pectoris. Circulation. 1995;91:2520-2527.
13. Hoffmeister HM, Ruf M, Wendel HP, Heller W, Seipel L. Streptokinase-induced activation of the kallikrein-kinin system and of the contact phase in patients with acute myocardial infarction. J Cardiovasc Pharmacol. 1998;31:764-772.
14. Huber K, Rose D, Resch I. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost. 1988;60:372-376.
15. Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost. 1987;58:817-821.
16. Rennie JA, Ogston D. Changes in coagulation factors following acute myocardial infarction in man. Haemostasis. 1976;5:258-264.
17. Gidron E, Margalit R, Oliven A, Shalitin Y. Effect of myocardial infarction on components of fibrinolytic system. Br Heart J. 1977;39: 19-24.
18. Gulba DC, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation. 1991;83:937-944.
19. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation. 1995;91: 28-36.
20. Agostoni A, Gardinali Frangi D, Cafaro C, Conciato L, Sponzilli C, Salvioni A, Cugno M, Ciardi M. Activation of complement and kininsystems after thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1994;90:2666-2670.
21. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb. 1992;12:548-553.
22. Eisenberg PR, Sherman L, Rich M, Schwanz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1255-1262.
23. Eisenberg PR, Sberman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987;10:527-529.
24. Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EKO, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood. 1991;78: 1490-1495.
25. Kerins DM, Roy L, Fitzgerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation. 1989;80:1718-1725.
26. Ring ME, Butman SM, Bruck DC, Feinberg WM, Corrigan JJ. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator. Thromb Haemost. 1988;60:428-433.
27. Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of cross-linked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res. 1987;46:109-120.
28. The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
29. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:322-331.
30. Kleniewsky J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992;120: 129-139.
31. Brommer EJP, Meijer P. Thrombin generation induced by the intrinsic or extrinsic coagulation pathway is accelerated by streptokinase, independently of plasminogen. Thromb Haemost. 1993;70:995-997.
32. Mirshahi M, Soria J, Soria C, Samama M, Caen JP. Degradation of fibrinogen by tissue plasminogen activator: consequences for fibrin polymerization. Thromb Res. 1990;52(suppl X):21-26.
33. Okada K, Lijnen HR, Moreau H, Vanderschueren S. Collen D. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. Thromb Haemost. 1996;76:857-859.
34. Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor-XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. J Am Coll Cardiol. 1991;18:454-458.
35. Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost. 1991;66:540-547.
36. Heller W, Fuhrer G, Gallimore MJ, Hoffmeister HE, Prekallikrein and kallikrein-like activity determination in heparinized plasma samples. Haemostasis. 1985;15:64-65.
37. Melandri G, Branzi A, Semprini F, Cervi V, Galiè N, Magnani B. Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J. 1990;64: 118-120.